Diagnosis, Classification & Disease Assessment

Nocturnal stools are one of the strongest single symptoms distinguishing organic from functional bowel disease. A patient who reliably sleeps through the night without waking for the toilet almost certainly does not have active IBD.

In Saudi Arabia, always include stool ova-and-parasite plus mycobacterial workup (QuantiFERON-TB or TST + chest X-ray) in the initial IBD evaluation. Hajj and Umrah travel, exposure to consanguineous relatives with latent TB, and high regional prevalence make this non-negotiable before starting immunosuppression.

If you do not intubate the terminal ileum, you have not completed an IBD colonoscopy. Ileal CD is missed without ileal intubation and biopsy — a "normal colonoscopy" in a patient with chronic diarrhea and no ileal view is not actually normal.

Final IBD diagnosis is a three-legged stool: compatible clinical picture + characteristic endoscopy + histology showing CHRONICITY. Missing any leg should delay, not accelerate, the diagnosis. Overzealous labelling of acute self-limiting colitis as IBD is a common pitfall that locks patients into lifelong therapy.

When a patient is reported as "Mayo 1," clarify whether it is Mayo endoscopic subscore 1 (mild endoscopic disease) or total Mayo Score 1 (essentially in remission). The two are very different and the ambiguity causes real harm in clinical communication.

In acute severe UC, UCEIS ≥7 combined with Truelove-Witts criteria and Oxford index criteria on day 3 identifies patients who will fail IV steroids and need rescue therapy. Use all three together — no single measure is enough.

SES-CD ignores perianal disease entirely. A patient with SES-CD 4 (endoscopic remission) but an active perianal fistula is NOT in remission. Always document perianal status separately using the Perianal Disease Activity Index (PDAI) or simple descriptive categories.

Every Saudi patient who undergoes ileocolonic resection for Crohn's must have a post-operative colonoscopy at 6-12 months. Rutgeerts i2b or higher at that visit predicts 50%+ risk of clinical recurrence — the window to intervene with biologic therapy is before symptoms return.

Every modern IBD clinic should aim to have at least one gastroenterologist credentialed in IUS. A patient can be scanned in 10 minutes at the point of care, results discussed immediately, and dose or drug decisions made in the same visit — no waiting weeks for MRE or colonoscopy.

Endoscopic scoring skills decay within 6 months without practice. Every SGA-accredited center should build recurring scoring-calibration sessions into the fellowship curriculum — this single habit is the difference between publishable trial-level endoscopic data and subjective informal impressions.

The "comb sign" (engorged vasa recta feeding an inflamed bowel segment on post-contrast imaging) is one of the most specific MRE signs for active Crohn's disease. When you see it, you are looking at a segment with active transmural inflammation — not just mucosal disease. This is the key MRE finding to show junior fellows.

Document cumulative radiation dose in the electronic chart of every IBD patient who has had more than one CTE or pelvic CT. Young patients accumulate radiation quickly — a 25-year-old with three CTEs and two pelvic CTs over 5 years may already have 60-80 mSv. Switching subsequent imaging to MRE is easy to recommend but easy to forget without this tracking.

Never perform capsule endoscopy in CD without first excluding stricture by imaging or patency capsule. A retained capsule in a proximal small-bowel stricture can precipitate obstruction and require surgical retrieval — a preventable complication that has led to malpractice claims globally.

Require the ESGAR/ECCO structured template for every IBD MRE/CTE in your institution. Audit compliance quarterly. A single year of structured reporting generates cleaner data, better inter-radiologist agreement, and drives meaningful quality improvement — it is the single most impactful radiology intervention for an IBD service.

For every biopsy in Saudi IBD workup where ITB is in the differential, send an extra tissue sample in saline (not formalin) for AFB stain, PCR, and culture. Formalin-fixed tissue cannot be cultured. This single process change is the difference between diagnosing TB pre-treatment and diagnosing disseminated TB after a disastrous biologic exposure.

In any IBD case where the story does not quite fit — ulcers too deep, too few, at the wrong location, or the patient has recurrent oral/genital aphthae or uveitis — pause and screen for Behçet formally with the International Study Group criteria before settling on an IBD label.

Any patient with new colitis within 12 weeks of starting a checkpoint inhibitor has ICI colitis until proven otherwise — not new-onset IBD. Coordinate urgently with oncology: steroids may need to start the same day, ICI must be held, and infliximab is second-line if steroids fail. Misdiagnosis as UC and delay in ICI-specific management can be fatal.

The two most common serious diagnostic errors in IBD practice are: (1) labelling acute self-limiting colitis as UC after one endoscopy, locking the patient into lifelong therapy; and (2) labelling ITB as CD and starting anti-TNF, causing disseminated TB. Both are prevented by requiring chronicity markers on histology and proactive TB screening.

Every biopsy report you read should explicitly comment on crypt architecture and the plasma-cell gradient. If the pathology report does not mention these two features, either the biopsy was not adequate or the pathologist needs feedback — these are the foundation for distinguishing acute from chronic colitis.

Basal plasmacytosis is the single most reliable chronicity marker. If plasma cells are packed between crypt bases and the muscularis mucosae, you are looking at chronic colitis. If the crypt bases look naked against the muscularis, you are probably looking at acute infectious colitis — do not label as IBD on that biopsy alone.

A single non-caseating granuloma in a mucosal biopsy does not clinch a CD diagnosis — it could be sarcoidosis, Behçet, TB, or a response to a foreign body. But a cluster of non-caseating granulomas in a treatment-naïve patient with supportive clinical and endoscopic features is strongly supportive of CD. Context and integration matter more than any single histologic finding.

Every long-standing IBD surveillance colonoscopy should use chromoendoscopy with targeted biopsies of visible abnormalities, not random 4-quadrant biopsies alone. The SCENIC consensus changed practice — if your center still does white-light + random biopsies only, the dysplasia you miss is directly proportional to that practice gap.